Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels

International Journal of Biological Markers

Volumn 26, Issue 2, 2011, Pages 117-123

  Cristaudo, Alfonso ^a   Foddis, Rudy ^a   Bonotti, Alessandra ^a   Simonini, Silvia ^a   Vivaldi, Agnese ^a   Guglielmi, Giovanni ^a   Bruno, Rossella ^a   Gemignani, Federica ^a   Landi, Stefano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Marker; Mesothelin; Polymorphism

Indexed keywords

ASBESTOS; DNA; MESOTHELIN; SOLUBLE MESOTHELIN RELATED PEPTIDE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; DNA SEQUENCE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT MESOTHELIOMA; MALIGNANT PLEURAL MESOTHELIOMA; NUCLEOTIDE SEQUENCE; PLEURA MESOTHELIOMA; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

5' FLANKING REGION; ASBESTOS; GENE FREQUENCY; GPI-LINKED PROTEINS; HUMANS; MALE; MESOTHELIOMA; MIDDLE AGED; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; PEPTIDES; PLEURAL NEOPLASMS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 79959311591     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8332     Document Type: Article

References (22)

1. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy Clin Cancer Res 2004; 10: 3937-42.
2. Urwin D, Lake RA. Structure of the mesothelin/MPF gene and characterization of its promoter. Mol Cell Biol Res Commun 2000; 3: 26-32.
3. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996; 93: 136-40.
4. Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem 1995; 270: 21984-90.
5. Scholler N, Fu N, Yang Y, et al Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A 1999; 96: 11531-6.
6. Robinson BWS, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 1612-6.
7. Creaney J, Lake R, Nowak A, et al. Soluble mesothelinrelated protein--a blood test for mesothelioma. Lung Cancer 2005; 49 (Suppl 1): S109-11.
8. Creaney J, Robinson BWS. Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med 2009; 15: 366-70.
9. Grigoriu BD, Scherpereel A. Diagnostic value of soluble mesothelin in malignant mesothelioma. Thorax 2008; 63: 87-8; author reply 87.
10. Amati M, Tomasetti M, Mariotti L, et al. Assessment of biomarkers in asbestos-exposed workers as indicators of cancer risk. Mutat Res 2008; 655: 52-8.
11. Creaney J, Robinson BWS. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein. Hematol OncolClin North Am 2005; 19: 1025-40.
12. Cristaudo A, Foddis R, Buselli R, et al. Medical surveillance of workers previously exposed to asbestos. Med Lav 2006; 97: 475-81.
13. Park E, Thomas PS, Creaney J, Johnson AR, Robinson BW, Yates DH. Factors affecting soluble mesothelin related protein levels in an asbestos-exposed population. Clin Chem Lab Med 2010; 48: 869-74.
14. Hollevoet K, Bernard D, De Geeter F, et al. Glomerular filtration rate is a confounder for the measurement of soluble mesothelin in serum. Clin Chem 2009; 55: 1431-3.
15. Cristaudo A, Foddis R, Bonotti A, et al. Polymorphisms in the putative micro-RNA-binding sites of mesothelin gene are associated with serum levels of mesothelin-related protein. Occup Environ Med 2010; 67: 233-6.
16. Cristaudo A, Foddis R, Vivaldi AR, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13: 5076-81.
17. Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant pleural mesothelioma. Clin Chem 2007; 53: 666-72.
18. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-5.
19. Scheet P, Stephens M. A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet 2006; 78: 629-44.
20. Youden WJ. Index for rating diagnostic tests. Cancer 1950; 3: 32-5.
21. SPSS/PC Statistical Package for the Social Sciences + update for 10.1, 2000. SPSS Inc, Chicago, IL, USA.
22. Jones NC, Rigby PW, Ziff EB. Trans-acting protein factors and the regulation of eukaryotic transcription: lessons from studies on DNA tumor viruses. Genes Dev 1988; 2: 267-81.